London, UK – NHS England has released new guidance on the use of AI-enabled ambient scribing products in health and care settings, impacting not only healthcare providers but also offering crucial insights for any UK business considering the adoption of ambient voice technologies (AVTs) for documentation and workflow support. This guidance, published on April 27, 2025, with its first version aimed specifically at NHS England, marks a significant step towards regulating and ensuring the safe deployment of Generative AI and Large Language Models (LLMs) in sensitive data environments.
While primarily designed for NHS Chief Information Officers (CIOs) and Chief Clinical Information Officers (CCIOs), the document, “Guidance on the use of AI-enabled ambient scribing products in health and care settings,” holds valuable lessons for UK small business owners, freelancers, and website operators navigating the complexities of UK GDPR and data protection when implementing AI solutions.
What Are Ambient Scribing Products?
Ambient scribing products are tools that utilise advanced speech technologies to automatically convert spoken words into text and other outputs with minimal user intervention. These can include AI scribes or AVTs, designed to assist with documentation and workflow. The latest generation of these products incorporates Generative AI and LLMs, offering powerful capabilities beyond traditional speech recognition.
For UK businesses, this could mean anything from AI-powered meeting transcription services to automated customer service note-taking tools. The guidance highlights that these products can capture and record speech interactions, convert them into text, generate summaries, format outputs, extract terms, and even populate information in records.
The UK GDPR and Data Protection Imperative
The NHS England guidance places a strong emphasis on data compliance and security, a paramount concern for any UK business handling personal data under UK GDPR. It stresses the early engagement with Information Governance (IG) and cybersecurity support to ensure legal and regulatory requirements are factored into procurement and implementation.
- Data Protection Impact Assessments (DPIAs): A recurring theme throughout the guidance is the mandatory completion of a DPIA. This is vital for any UK business implementing new technologies that process personal data. It’s about proactively identifying and mitigating data protection risks. The guidance notes that example DPIA templates will be published separately, which will be a valuable resource for all.
- Transparency is Key: Businesses must be transparent about how information is used and shared, especially with the introduction of ambient scribing products. This includes updating privacy notices and explaining to individuals how their data will be used before processing takes place, giving them the chance to object. Think about whether your website’s privacy policy clearly outlines how any AI tools process user data.
- Robust Security Measures: The guidance calls for robust measures to protect patient data, including encryption, access controls, and regular security audits. For UK businesses, this translates to ensuring your AI solution providers comply with recognised security standards like Cyber Essentials Plus certification or similar ISO standards.
- Legal Basis for Processing: Understanding the legal basis for using and retaining data is critical. Businesses must be clear whether patient (or customer) consent is needed for the use and retention of data by these AI tools. This links directly to UK GDPR’s lawful bases for processing personal data.
Myth vs. Fact: Is Your AI Tool a Medical Device?
A significant section of the NHS guidance delves into medical device regulations, which might seem niche but holds a crucial “myth vs. fact” element for broader AI adoption.
- Myth: All AI scribing products are medical devices.
- Fact: A product’s intended purpose and functionality determine its medical device status. Simple text transcription tools, easily verified by users, are likely not medical devices.
- Crucial Distinction: However, if a Generative AI tool performs further processing, such as summarisation, or informs medical decisions, it likely would qualify as a medical device. This distinction is vital because medical devices require registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and adherence to specific safety requirements.
For non-healthcare UK businesses, this distinction provides a useful analogy. If your AI tool simply transcribes a meeting, it’s less likely to fall under stringent regulation. But if it starts generating “insights” or “recommendations” that could significantly impact your business decisions or customer interactions, you need to consider the potential for increased regulatory scrutiny and liability.
Key Considerations for UK Businesses
The NHS guidance offers a practical checklist of considerations that can be adapted by any UK business implementing AI:
- Risk Identification and Assessment: Beyond DPIAs, consider technical risks like output errors, system unavailability, integration failures, or data loss. Be aware that Generative AI can introduce unintentional new functions or be prompted to go beyond its intended purpose.
- Integration and Performance: Ensure your AI solution integrates seamlessly with existing IT infrastructure and workflows. Define clear performance metrics for accuracy, reliability, and uptime. For instance, if you’re using an AI tool for customer service, how accurate are its responses? How often is it down?
- Portability, Scalability, and Flexibility: Can the system handle increasing data volumes as your business grows? Is it compatible with other technologies you might adopt in the future?
- Support and Maintenance: Clarify responsibilities for data storage, access, and ongoing maintenance with your supplier. Ensure Service Level Agreements (SLAs) cover system uptime, response times, and ongoing training.
- Monitoring and Bias Mitigation: AI-enabled products have a high potential for bias due to limitations in training data. For example, AVTs may struggle with certain accents or dialects. For UK businesses, this means actively monitoring the AI’s performance to ensure fairness and accuracy across your diverse customer base.
- User Training: Providing appropriate training to staff on the approved use of AI tools is crucial. Emphasise the ongoing responsibility for users to review and revise AI outputs.
Navigating Liability Under UK GDPR
A critical point for small business owners and freelancers is the aspect of liability. The guidance states that NHS organisations may still be liable for claims arising from AI product use, especially concerning non-delegable duties of care. This financial exposure can be mitigated by clear and comprehensive contracting arrangements with suppliers outlining their roles, responsibilities, and liability.
This is a direct parallel for UK businesses. While an AI tool might assist, the ultimate responsibility for data protection compliance and the accuracy of information often rests with the data controller – your business. Robust contracts with your AI solution providers are essential to define responsibilities and liabilities, particularly concerning data breaches or inaccuracies leading to UK GDPR infringements.
Looking Ahead for UK Businesses
The NHS England guidance is the first in a series of documents, with further support templates, tools (including DPIA templates), and evaluation guidance expected in the next six months. A community of practice will also be established to share insights and best practices.
For UK small businesses, freelancers, and marketers, this ongoing development from a leading public sector body provides invaluable real-world insights into AI governance and data protection. By adapting the principles outlined in this NHS guidance, businesses can proactively navigate the evolving landscape of AI adoption, ensuring compliance with UK GDPR and building trust with their customers. Staying informed about these developments will be key to harnessing the benefits of AI while effectively managing associated risks.